STOCK TITAN

Pacira Biosciences Inc - PCRX STOCK NEWS

Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.

Pacira BioSciences Inc (NASDAQ: PCRX) is a leader in non-opioid pain management, offering innovative therapies that reduce reliance on traditional opioids. This page provides investors and healthcare professionals with timely updates on the company’s latest developments, including regulatory milestones, clinical advancements, and strategic initiatives.

Access PCRX’s official press releases, earnings reports, and analysis of key events shaping its position in the specialty pharmaceutical sector. Track updates on flagship products like EXPAREL® (long-acting local anesthetic) and iovera® (targeted cold therapy), along with emerging pipeline candidates such as PCRX-201 for osteoarthritis.

Discover how Pacira’s proprietary drug delivery platforms and commitment to evidence-based solutions address critical needs in postsurgical recovery and chronic pain management. Stay informed about partnerships, regulatory approvals, and market expansion efforts driving the company’s growth.

Bookmark this page for direct access to PCRX’s verified news, ensuring you never miss developments impacting its role in transforming pain treatment. Visit regularly to monitor progress in non-opioid innovation and regenerative health solutions.

Rhea-AI Summary

Pacira BioSciences has received FDA approval for an enhanced manufacturing process for its product EXPAREL (bupivacaine liposome injectable suspension), allowing it to double production capacity at a new 200-liter facility in Swindon, England. This move is anticipated to enhance gross margins and extend market exclusivity to January 2041 with the issuance of a new patent. The company aims to commence commercial sales of EXPAREL produced in this facility by the end of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) reported significant findings on the iovera° system from a study focused on total knee arthroplasty (TKA). The addition of preoperative iovera° treatment to a multimodal pain management protocol led to a remarkable 51% reduction in daily opioid consumption and notably decreased pain levels and hospital stay lengths. Analysis of 267 patients showed less than 17% had a hospital stay of two or more days compared to 99% in the control group. These outcomes highlight iovera°'s efficacy in enhancing post-surgical recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its second quarter financial results on August 3, 2021, before U.S. market opening. Following the earnings release, a live conference call will occur at 8:30 a.m. ET. Participants can join the call by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international), using passcode 9991311. A replay will be available for one week post-call. Pacira is known for its commitment to non-opioid pain management, with flagship product EXPAREL® launched in 2012, and acquisition of iovera°® system in 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences earnings
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net revenue of $135.6 million for Q2 2021, primarily driven by EXPAREL sales of $130.1 million. Average daily sales of EXPAREL surged to 178% of last year for Q2 and to 120% for June. Despite ongoing challenges due to the COVID-19 pandemic impacting elective surgeries, the company remains optimistic about future growth as conditions normalize. The report also highlights increased interest in iovera° and the company's commitment to non-opioid pain management solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. (Nasdaq: PCRX) has entered a distribution agreement with Eurofarma Laboratories S.A. for the commercialization of EXPAREL® in 19 Latin American countries, including Brazil and Mexico. This partnership aims to enhance Pacira's presence in a rapidly growing market, allowing Eurofarma to leverage its extensive experience in introducing innovative products. Pacira will earn royalties and milestone payments based on Eurofarma's success in this region, reinforcing its commitment to providing non-opioid pain management solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $41.2 million and $1.0 million, respectively, for May 2021. Sales for EXPAREL showed strong growth, with average daily sales at 162% of May 2020 and 105% of April 2021. This growth is attributed to increased demand in outpatient and non-elective procedures, despite ongoing impacts from the COVID-19 pandemic. The company continues to report monthly sales data to provide clarity on market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
Rhea-AI Summary

Pacira BioSciences announced topline results from its Phase 3 STRIDE study for EXPAREL, which failed to meet the primary endpoint of pain reduction from 0 to 96 hours compared to bupivacaine HCl. However, significant reductions in pain and opioid consumption were observed from 24 to 96 hours (p<0.01) and cumulative pain scores from 12 to 96 hours (p<0.02). Safety results showed no serious adverse events. The company plans to further analyze the data and discuss next steps with the FDA, emphasizing EXPAREL's potential in opioid-sparing pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
-
Rhea-AI Summary

PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:30 AM ET. The event can be accessed via the company's website, with a replay available for two weeks after the presentation. Pacira is a leader in non-opioid pain management, known for its long-acting local analgesic EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance and enhance patient care through innovative solutions, including the iovera°® cryoanalgesia device acquired in 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences
-
Rhea-AI Summary

Pacira BioSciences has received a Notice of Allowance from the USPTO for a patent regarding its EXPAREL manufacturing process, extending protection until January 22, 2041. This patent is a key component of the company's strategy to maintain market exclusivity for EXPAREL, a non-opioid pain management solution. The company has invested over $100 million in developing a more efficient manufacturing method. Additionally, Pacira is awaiting FDA approval for its new manufacturing process, with a PDUFA date set for August 6, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 10:20 AM ET. The virtual event will feature live audio accessible via the company’s website. A replay will be available for two weeks post-event.

Pacira is a leader in non-opioid pain management solutions, known for its long-acting local analgesic, EXPAREL®, which was launched in April 2012. In 2019, the company expanded its portfolio by acquiring the iovera°® system, enhancing its commitment to innovative pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
Pacira Biosciences Inc

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.14B
44.69M
3.18%
111.99%
12.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TAMPA